Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214777 | 1.00 | PDE8B (0.48) | PDE8BHPGDKDM1AEPHX1ATM | |
| SCHEMBL344947 | 0.98 | PDE8B (0.49) | PDE8BHPGDKDM1AEPHX1ATM | |
| SCHEMBL80021 | 0.98 | PDE8B (0.49) | PDE8BHPGDKDM1AEPHX1ATM | |
| SCHEMBL283705 | 0.98 | PDE8B (0.49) | PDE8BHPGDKDM1AEPHX1ATM | |
| Hydrochloric Acid SCHEMBL3564519 | 0.97 | PDE8B (0.48) | PDE8BHPGDKDM1AEPHX1ATM | |
| SCHEMBL337349 | 0.94 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL337037 | 0.94 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL205359 | 0.94 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1026857 | 0.92 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1027414 | 0.92 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | PDE8B 1262/4885HPGD 1387/4885KDM1A 2725/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | PDE8B 1262/4885HPGD 1387/4885KDM1A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.